ChemicalBook > Product Catalog >API >Antineoplastic agents >Other antineoplastic Drugs >Bortezomib

Bortezomib

Bortezomib Suppliers list
Company Name: Beijing Cooperate Pharmaceutical Co.,Ltd.
Tel: +86-10-60279497 +86(0)15646567669
Email: sales01@cooperate-pharm.com
Products Intro: Product Name:Bortezomib
CAS:179324-69-7
Purity:98% Package:100G;1KG;5KG;10KG;25KG;50KG;100KG
Company Name: pegpharm Co., Ltd
Tel: 0086-512-58984909
Email: sales@pegpharm.com
Products Intro: Product Name:Bortezomib
CAS:179324-69-7
Purity:98% Package:1g,5g,25g,100g Remarks:B0229
Company Name: Capot Chemical Co.,Ltd.
Tel: +86 (0)571-855 867 18
Email: sales@capotchem.com
Products Intro: Product Name:Bortezomib
CAS:179324-69-7
Purity:97%(Min,HPLC) Package:100g;1kg;5kg,10kg,25kg,50kg
Company Name: Sichuan Tuskwei Import and Export Trade Co., Ltd.
Tel: 86-311-83306736
Email: catherine@tuskwei.com
Products Intro: Product Name:Bortezomib
CAS:179324-69-7
Purity:99.67% Package:In Aluminium Foil Packing
Company Name: Henan Tianfu Chemical Co.,Ltd.
Tel: 0371-55170693
Email: info@tianfuchem.com
Products Intro: Product Name:Bortezomib
CAS:179324-69-7
Purity:99% Package:500G;1KG;5KG;25KG
Bortezomib Basic information
Description Drug for Cancer treatment
Product Name:Bortezomib
Synonyms:Boronic acid, B-[(1R)-3-Methyl-1-[[(2S)-1-oxo-3-phenyl-2-[(2-pyrazinylcarbonyl)aMino]propyl]aMino]bu;MG-341 PS-341;BortezoMib Base;BortezoMib-D8;bortezoMib(other);MLM341;BortezoMib R;BortezoMib (PS-341, LDP-341, MLM341)
CAS:179324-69-7
MF:C19H25BN4O4
MW:384.24
EINECS:
Product Categories:ProteasomeInhibitors;Apis;Inhibitor;Final material;API;peptides;Boron Derivatives;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;Pepetides
Mol File:179324-69-7.mol
Bortezomib Structure
Bortezomib Chemical Properties
Melting point 122-124°C
density 1.214
RTECS ED7771666
storage temp. Hygroscopic, -20°C Freezer, Under Inert Atmosphere
solubility Soluble in chloroform, dimethyl sulfoxide, ethanol and methanol.
Stability:Hygroscopic and Moisture Sensitive
CAS DataBase Reference179324-69-7(CAS DataBase Reference)
Safety Information
Risk Statements 23/24/25-48/23/24/25
Safety Statements 9-27-36/37-45-60
HazardClass 6.1
Hazardous Substances Data179324-69-7(Hazardous Substances Data)
MSDS Information
Bortezomib Usage And Synthesis
DescriptionBortezomib, a modified dipeptidyl boronic acid, is a therapeutic proteasome inhibitors used for the treatment of cancers. It is indicated for the treatment of relapsed multiple myeloma and mantle cell lymphoma. It is capable of inhibiting the mammalian 26S proteasome, which is important in regulating the intracellular concentration of specific proteins to maintain homeostasis within cells. The disruption of 26S proteasome function disrupts normal cellular homeostasis, leading to cytotoxic effect on various kinds of cancer cells. 
Drug for Cancer treatmentBortezomib is a drug for treatment of hematopoietic malignancies with the appearance being white or white-like crystalline powder. It is easily soluble in dimethyl sulfoxide, ethanol, but insoluble in aqueous solution. This product is the reversible inhibitor of the mammal cell 26S proteasome chymotrypsin-like activity. 26S proteasome is a large protein complex which can degrade ubiquitin. Ubiquitin proteasome pathway plays an important role in regulation of the intracellular concentration of specific proteins in order to maintain the stability of the intracellular environment. Proteolytic affects intracellular multi-level signalling cascade. The disruption of the normal intracellular environment can lead to cell death while the inhibition of the 26S proteasome can prevent the hydrolysis of specific proteins. In vitro tests have proved bortezomib exhibits cytotoxicity to multiple types of cancer cells. The in vivo models of preclinical tumor have proved that bortezomib is capable of delaying the tumor growth of multiple myeloma which is suitable for the treatment of multiple myeloma.
The above information is edited by the Chemicalbook of Dai Xiongfeng.
Chemical PropertiesYellow Solid
UsesBortezomib is the first proteasome inhibitor to be approved b the US FDA for multiple myeloma, a blood cancer. A reversible inhibitor of the 26S proteasome-a barrel-shaped multiprotein particle found in the nucleus and cytosol of all eukaryotic cells. T
DefinitionChEBI: L-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at Nalpha by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid tha reversibly inhibits the 26S proteasome.
Bortezomib Preparation Products And Raw materials
Tag:Bortezomib(179324-69-7) Related Product Information
Bortezomib Bensulfuron methyl tert-Butylchlorodiphenylsilane EC 2.6.1.2 Zolmitriptan Propyl butyrate 3,4'-DIAMINODIPHENYLMETHANE Methyl salicylate Propyl gallate Methyl Kresoxim-methyl Thiophanate-methyl Glucosamine Phenylacetone ACETAMINOPHENOL BP/USP Methyl bromide Isopropanol PHENYL VALERATE